Tibotec is a pharmaceutical research and development company focused on the discovery and development of highly active HIV/AIDS drugs and novel anti-infectives for diseases of high unmet medical need. Tibotec is committed to improving patient care and quality of life.
The company has two antiretroviral compounds in phase II development for HIV/AIDS. TMC125 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and TMC114 is a protease inhibitor (PI). Both compounds are highly active against both wild-type and drug resistant HIV.
A multi-disciplinary scientific team with substantial experience and know-how in drug discovery, resistance biology and HIV research applies the latest techniques in ultra-high-throughput screening, antiviral profiling, molecular biology, drug design and molecular modeling to drug discovery . The company has actively developed an extensive network of research collaborations, partnerships and license agreements with academic institutions, public organizations, and companies in pharmaceuticals and biotechnology.
This site is published by Johnson & Johnson Pharmaceutical Services, L.L.C., which is solely responsible for its contents.
This page was last modified on Apr 23 2008 at 10:41:22 EDT .
